Stop blaming and start taming, with SOLIQUA 100/33

SOLIQUA 100/33 works 5 ways in your body to control blood sugar and help lower A1c.

Hear Joanne talk about making the change to injectable therapy

Meet Joanne. Type 2 diabetes runs in her family, but she resisted making the change from diabetes pills for years. But if she knew then what she knows now, she may have made the change to injectable therapy sooner.

    JOANNE: If I knew then what I know now, I would have taken insulin sooner. They made it like it was a last resort. You take this and you have really messed up, and that’s not true.

    Like certain diseases run in different families, and for me it’s like, “Who doesn't have diabetes?” you know? ‘Cause now it’s affecting my cousins, my first cousins and all, because our parents and grandparents. Even though the family history was there, nobody was really taking care of themselves or really understood what it was and was doing what they were supposed to do. So, needless to say, I kind of did the same thing for six years.

    Look at my daughter, how cute…and she, too, now has type 2 diabetes, and she has an 8-year-old. But she went totally all out as to make sure he eats healthy. Her experience is totally different because he didn’t get anything sweet until he was a year old – a piece of cake. If I knew then what I know now, I’d tell her, “You’re going to be the one that has the child that breaks the cycle.”

    And I’m proud to say…I helped her, yes. You're gonna have to make changes…and they’re not hard. It’s things that we should be doing anyway. …you know, It’s like taking on a new project. Do 60 percent, 70 percent. Get up to at least 80 percent to where you’re doing 80 percent right. Let’s hit the ground running with the education. Let’s change the way we’re eating.

    Traditionally, being African-American, we go all out for the holidays, all right. You have a dessert table, the food. Do you need four or five meats? No. Do you need the chocolate cake, banana pudding, peach cobbler? Hecks no. What I did, I skipped the food and had all the desserts. So if I knew then what I know now, I would eat first, and then I’d have a little bit. Because we can have a little bit. You just cannot have a lot.

    If I knew then what I know now, insulin would be one of the things that I would take. One of the tools that I would choose to use to help me with my diabetes. It’s gonna be a tool that you can take out of that toolbox and use. Now, of course, that’s not a miracle, that if you do this, you don't have to do anything else. You still have to eat healthy, you still have to exercise. I may ride a bike, I may lay on the floor pretendin’ like I’m doing yoga. I say pretendin’ because I don't know whether I’m doing it right or not. I’m doing it with the DVD. But I’m doing stuff.

    Because look at me. I’m 68, I’m still here and I’m doing it.

    SAUS.SQA.19.08.4336

SOLIQUA 100/33 helped nearly 3 out of 4 people taking pills for their type 2 diabetes lower their A1c to below 7%


In a clinical study of adult patients with type 2 diabetes (Lixilan O), 74% of patients using SOLIQUA 100/33 lowered their A1c below 7%, while 59% of patients on Lantus® and 33% of patients on lixisenatide reached an A1c below 7%. The A1c average was reduced from a starting point of 8.1% to 6.5% in patients taking SOLIQUA 100/33, from 8.1% to 6.8% in patients taking Lantus, and from 8.1% to 7.3% in patients taking lixisenatide at the end of 30 weeks.

Your doctor may prescribe a dose of insulin that is different from the doses used in the study. The results seen in the trial may not reflect your results.

The most common side effects of SOLIQUA 100/33 include low blood sugar (hypoglycemia), nausea, diarrhea, upper respiratory infection, stuffy or runny nose, and headache. These are not all the possible side effects of using SOLIQUA 100/33.

Individual results may vary.
The clinical study (Lixilan O) showed that in patients treated with metformin, SOLIQUA 100/33 improved blood sugar control compared to its individual components, a long-acting insulin (Lantus), and a non-insulin, diabetes medicine (lixisenatide). The study included 1,479 patients with type 2 diabetes who were on metformin alone or a 2nd oral diabetes medication which was subsequently discontinued and whose A1c was not at goal. After 4 weeks of taking metformin alone, during which time the metformin dose was optimized, 1,170 patients who had still not achieved their A1c goal with A1c 7-10%, had a fasting blood sugar ≤ 250 mg/dL, and were on ≥ 1500 mg metformin continued in the study. For the next 30 weeks patients continued taking metformin and were also treated with either SOLIQUA 100/33 (469 patients), Lantus (467 patients), or lixisenatide (234 patients). In the patients receiving insulin glargine 100 units/mL in the form of Lantus or SOLIQUA 100/33, the insulin glargine dose was adjusted in accordance with fasting self-monitored blood glucose measures aiming for a target of (80-100 mg/dL) with a dose cap of 60 units in both the Lantus and SOLIQUA 100/33 groups. The study showed that combining lixisenatide with Lantus in SOLIQUA 100/33 can help lower blood sugar even further than its individual components in patients taking metformin.

SOLIQUA 100/33 savings

Eligible commercially insured patients may pay as little as $9* for a 30-day supply. Maximum savings of $365 per pack.
*Terms and conditions apply.

SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, which may improve blood sugar (glucose) control in adults with type 2 diabetes when used with diet and exercise.

  • It has not been studied in people with a history of pancreatitis.
  • It is not recommended for people who also take lixisenatide or other medicines called GLP-1 receptor agonists.
  • It is not for use in people with type 1 diabetes, or people with diabetic ketoacidosis.
  • It has not been studied in people who have a stomach problem that causes slow emptying (gastroparesis) and is not for people with slow emptying of the stomach.
  • It has not been studied in people who also take a short-acting (prandial) insulin.
  • It is not known if SOLIQUA 100/33 is safe and effective in children under 18 years of age.

Important Safety Information

Important Safety Information

Important Safety Information for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL

What is the most important information I should know about SOLIQUA 100/33? Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be severe and lead to death.

Before using SOLIQUA 100/33, tell your doctor if you have had pancreatitis, stones in your gallbladder (cholelithiasis), or a history of alcoholism. These medical problems may make you more likely to get pancreatitis.

Stop taking SOLIQUA 100/33 and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.

Who should not use SOLIQUA 100/33?
Do not use SOLIQUA 100/33 if you:

  • are having an episode of low blood sugar (hypoglycemia)
  • are allergic to insulin glargine, lixisenatide, or any of the ingredients in SOLIQUA 100/33. Symptoms of a severe allergic reaction with SOLIQUA 100/33 may include swelling of the face, lips, tongue, or throat, fainting or feeling dizzy, problems breathing or swallowing, very rapid heartbeat, severe rash or itching, or low blood pressure.

Before using SOLIQUA 100/33, tell your healthcare provider about all your medical conditions, including if you:

  • have or have had problems with your pancreas, your kidneys, or your liver, stones in your gallbladder, or a history of alcoholism.
  • have heart failure or other heart problems. If you have heart failure, it may get worse while you take thiazolidinediones (TZDs).
  • have severe problems with your stomach, such as slowed emptying of your stomach or problems digesting food.
  • are taking certain medicines called glucagon-like peptide 1 receptor agonists (GLP-1 receptor agonists).
  • have had an allergic reaction to a GLP-1 receptor agonist.
  • are pregnant or breastfeeding or plan to become pregnant or to breastfeed. It is not known if SOLIQUA 100/33 will harm your unborn baby or pass into your breast milk.

Tell your healthcare provider about all the medicines you take, including all prescription and over-thecounter medicines, vitamins, and herbal supplements. SOLIQUA 100/33 may affect the way some medicines work. Before using SOLIQUA 100/33, talk to your healthcare provider about low blood sugar and how to manage it.

How should I use SOLIQUA 100/33?

  • Do not change your dose without first talking to your healthcare provider.
  • Check the pen label each time you inject to make sure you are using the correct medicine.
  • Do not take more than 60 units of SOLIQUA 100/33 each day. Do not take SOLIQUA 100/33 with other GLP-1 receptor agonists.
  • Only use SOLIQUA 100/33 that is clear and colorless to almost colorless. If you see small particles, return it to your pharmacy for replacement.
  • Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting pitted or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.
  • Do not remove SOLIQUA 100/33 from the pen with a syringe.
  • Do not re-use or share needles with other people. You may give other people a serious infection, or get a serious infection from them.
    Ask your healthcare provider what your blood sugar should be and when you should check.
  • Check your blood sugar levels. Ask your healthcare provider what your blood sugar should be and when you should check.

What are the possible side effects of SOLIQUA 100/33?
SOLIQUA 100/33 can cause serious side effects, including:

  • Serious allergic reactions. Stop taking SOLIQUA 100/33 and get help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
  • Low blood sugar (hypoglycemia). Your risk for getting low blood sugar is higher if you take another medicine that can cause low blood sugar. Signs and symptoms of low blood sugar may include headache, dizziness, drowsiness, sweating, weakness, irritability, hunger, blurred vision, fast heartbeat, feeling jittery, confusion, and anxiety.
  • Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may worsen kidney problems.
  • Low potassium in your blood (hypokalemia).
  • Heart failure. Taking certain diabetes pills called TZDs (thiazolidinediones) with SOLIQUA 100/33 may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure, it may get worse while you take TZDs with SOLIQUA 100/33. Tell your healthcare provider if you have any new or worse symptoms of heart failure, including shortness of breath, swelling of your ankles or feet, or sudden weight gain. Treatment with TZDs and SOLIQUA 100/33 may need to be adjusted or stopped if you have new or worse heart failure.

The most common side effects of SOLIQUA 100/33 include low blood sugar (hypoglycemia), nausea, diarrhea, upper respiratory infection, stuffy or runny nose, and headache. Nausea and diarrhea usually happen more often when you first start using SOLIQUA 100/33.

Click here for Full Prescribing Information for SOLIQUA 100/33.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

If you are a patient experiencing problems with a Sanofi U.S. product, please contact Sanofi U.S. at 1-800-633-1610.

The health information contained herein is provided for general educational purposes only. Your healthcare provider is the single best source of information regarding your health. Please consult your healthcare provider if you have any questions about your health or treatment.

* This offer is for commercially insured patients and is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs, including any state pharmaceutical programs. Void where prohibited by law. Savings card carries maximum savings of $365 per pack, up to 2 packs for each 30-day supply, for the duration of the program. Savings may vary depending on patient’s out-of-pocket costs. Upon registration, patient receives all program details. Sanofi US reserves the right to rescind, revoke, or amend the program without notice.

Important Safety Information

Important Safety Information

Important Safety Information for SOLIQUA 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL

What is the most important information I should know about SOLIQUA 100/33? Do not share your SOLIQUA 100/33 pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

SOLIQUA 100/33 can cause serious side effects, including inflammation of the pancreas, which may be severe and lead to death.

Before using SOLIQUA 100/33, tell your doctor if you have had pancreatitis, stones in your gallbladder (cholelithiasis), or a history of alcoholism. These medical problems may make you more likely to get pancreatitis.

Stop taking SOLIQUA 100/33 and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt in the back area. The pain may happen with or without vomiting.

Who should not use SOLIQUA 100/33?
Do not use SOLIQUA 100/33 if you:

  • are having an episode of low blood sugar (hypoglycemia)
  • are allergic to insulin glargine, lixisenatide, or any of the ingredients in SOLIQUA 100/33. Symptoms of a severe allergic reaction with SOLIQUA 100/33 may include swelling of the face, lips, tongue, or throat, fainting or feeling dizzy, problems breathing or swallowing, very rapid heartbeat, severe rash or itching, or low blood pressure.

Before using SOLIQUA 100/33, tell your healthcare provider about all your medical conditions, including if you:

  • have or have had problems with your pancreas, your kidneys, or your liver, stones in your gallbladder, or a history of alcoholism.
  • have heart failure or other heart problems. If you have heart failure, it may get worse while you take thiazolidinediones (TZDs).
  • have severe problems with your stomach, such as slowed emptying of your stomach or problems digesting food.
  • are taking certain medicines called glucagon-like peptide 1 receptor agonists (GLP-1 receptor agonists).
  • have had an allergic reaction to a GLP-1 receptor agonist.
  • are pregnant or breastfeeding or plan to become pregnant or to breastfeed. It is not known if SOLIQUA 100/33 will harm your unborn baby or pass into your breast milk.

Tell your healthcare provider about all the medicines you take, including all prescription and over-thecounter medicines, vitamins, and herbal supplements. SOLIQUA 100/33 may affect the way some medicines work. Before using SOLIQUA 100/33, talk to your healthcare provider about low blood sugar and how to manage it.

How should I use SOLIQUA 100/33?

  • Do not change your dose without first talking to your healthcare provider.
  • Check the pen label each time you inject to make sure you are using the correct medicine.
  • Do not take more than 60 units of SOLIQUA 100/33 each day. Do not take SOLIQUA 100/33 with other GLP-1 receptor agonists.
  • Only use SOLIQUA 100/33 that is clear and colorless to almost colorless. If you see small particles, return it to your pharmacy for replacement.
  • Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting pitted or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.
  • Do not remove SOLIQUA 100/33 from the pen with a syringe.
  • Do not re-use or share needles with other people. You may give other people a serious infection, or get a serious infection from them.
    Ask your healthcare provider what your blood sugar should be and when you should check.
  • Check your blood sugar levels. Ask your healthcare provider what your blood sugar should be and when you should check.

What are the possible side effects of SOLIQUA 100/33?
SOLIQUA 100/33 can cause serious side effects, including:

  • Serious allergic reactions. Stop taking SOLIQUA 100/33 and get help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat.
  • Low blood sugar (hypoglycemia). Your risk for getting low blood sugar is higher if you take another medicine that can cause low blood sugar. Signs and symptoms of low blood sugar may include headache, dizziness, drowsiness, sweating, weakness, irritability, hunger, blurred vision, fast heartbeat, feeling jittery, confusion, and anxiety.
  • Kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may worsen kidney problems.
  • Low potassium in your blood (hypokalemia).
  • Heart failure. Taking certain diabetes pills called TZDs (thiazolidinediones) with SOLIQUA 100/33 may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure, it may get worse while you take TZDs with SOLIQUA 100/33. Tell your healthcare provider if you have any new or worse symptoms of heart failure, including shortness of breath, swelling of your ankles or feet, or sudden weight gain. Treatment with TZDs and SOLIQUA 100/33 may need to be adjusted or stopped if you have new or worse heart failure.

The most common side effects of SOLIQUA 100/33 include low blood sugar (hypoglycemia), nausea, diarrhea, upper respiratory infection, stuffy or runny nose, and headache. Nausea and diarrhea usually happen more often when you first start using SOLIQUA 100/33.

Click here for Full Prescribing Information for SOLIQUA 100/33.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

If you are a patient experiencing problems with a Sanofi U.S. product, please contact Sanofi U.S. at 1-800-633-1610.

The health information contained herein is provided for general educational purposes only. Your healthcare provider is the single best source of information regarding your health. Please consult your healthcare provider if you have any questions about your health or treatment.

* This offer is for commercially insured patients and is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs, including any state pharmaceutical programs. Void where prohibited by law. Savings card carries maximum savings of $365 per pack, up to 2 packs for each 30-day supply, for the duration of the program. Savings may vary depending on patient’s out-of-pocket costs. Upon registration, patient receives all program details. Sanofi US reserves the right to rescind, revoke, or amend the program without notice.